Influenza virus neuraminidase inhibitors - PubMed (original) (raw)
Review
Influenza virus neuraminidase inhibitors
L V Gubareva et al. Lancet. 2000.
Abstract
Neuraminidase promotes influenza virus release from infected cells and facilitates virus spread within the respiratory tract. Several potent and specific inhibitors of this enzyme have been developed, and two (zanamivir and oseltamivir) have been approved for human use. Unlike amantadine and rimantadine that target the M2 protein of influenza A viruses, these drugs inhibit replication of both influenza A and B viruses. Zanamivir is delivered by inhalation because of its low oral bioavailability whereas oseltamivir is administered by mouth. Early treatment with either drug reduces the severity and duration of influenza symptoms and associated complications. Both agents are effective for chemoprophylaxis. Because of a broader antiviral spectrum, better tolerance, and less potential for emergence of resistance than is seen with the M2 inhibitors, the neuraminidase inhibitors represent an important advance in the treatment of influenza.
Comment in
- Neuraminidase inhibitor and amantadine.
Dawson J. Dawson J. Lancet. 2000 Jun 24;355(9222):2254. doi: 10.1016/S0140-6736(05)72755-0. Lancet. 2000. PMID: 10881922 No abstract available.
Similar articles
- Neuraminidase inhibitors for treatment of influenza A and B infections.
[No authors listed] [No authors listed] MMWR Recomm Rep. 1999 Dec 17;48(RR-14):1-9. MMWR Recomm Rep. 1999. PMID: 10632443 - Neuraminidase inhibitors: zanamivir and oseltamivir.
McNicholl IR, McNicholl JJ. McNicholl IR, et al. Ann Pharmacother. 2001 Jan;35(1):57-70. doi: 10.1345/aph.10118. Ann Pharmacother. 2001. PMID: 11197587 Review. - [Neuraminidase inhibitors in therapy of influenza].
Fladerer P, Wenisch C. Fladerer P, et al. Acta Med Austriaca. 2000;27(5):133-40. Acta Med Austriaca. 2000. PMID: 11261262 Review. German. - [Neuraminidase inhibitor].
Kaji M. Kaji M. Nihon Rinsho. 2000 Nov;58(11):2293-8. Nihon Rinsho. 2000. PMID: 11225320 Review. Japanese. - Updated treatment for influenza A and B.
Montalto NJ, Gum KD, Ashley JV. Montalto NJ, et al. Am Fam Physician. 2000 Dec 1;62(11):2467-76. Am Fam Physician. 2000. PMID: 11130232 Review.
Cited by
- Adverse events associated with oseltamivir and baloxavir marboxil in against influenza virus therapy: A pharmacovigilance study using the FAERS database.
Zhou Y, Jin L, Lai X, Li Y, Sheng L, Xie G, Fang J. Zhou Y, et al. PLoS One. 2024 Nov 13;19(11):e0308998. doi: 10.1371/journal.pone.0308998. eCollection 2024. PLoS One. 2024. PMID: 39536015 Free PMC article. - Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.
Suri C, Pande B, Sahithi LS, Sahu T, Verma HK. Suri C, et al. Microorganisms. 2024 Oct 8;12(10):2030. doi: 10.3390/microorganisms12102030. Microorganisms. 2024. PMID: 39458339 Free PMC article. Review. - RNA N6-methyladenosine methylation in influenza A virus infection.
Liu X, Chen W, Li K, Sheng J. Liu X, et al. Front Microbiol. 2024 Jun 18;15:1401997. doi: 10.3389/fmicb.2024.1401997. eCollection 2024. Front Microbiol. 2024. PMID: 38957616 Free PMC article. Review. - Unveiling potent inhibitors for schistosomiasis through ligand-based drug design, molecular docking, molecular dynamics simulations and pharmacokinetics predictions.
Ja'afaru SC, Uzairu A, Bayil I, Sallau MS, Ndukwe GI, Ibrahim MT, Moin AT, Mollah AKMM, Absar N. Ja'afaru SC, et al. PLoS One. 2024 Jun 26;19(6):e0302390. doi: 10.1371/journal.pone.0302390. eCollection 2024. PLoS One. 2024. PMID: 38923997 Free PMC article. - The Three-Dimensional Reference Interaction Site Model Approach as a Promising Tool for Studying Hydrated Viruses and Their Complexes with Ligands.
Fedotova MV, Chuev GN. Fedotova MV, et al. Int J Mol Sci. 2024 Mar 26;25(7):3697. doi: 10.3390/ijms25073697. Int J Mol Sci. 2024. PMID: 38612508 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical